TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01958190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus and Sirolimus
Description: Arm 1 once daily combination therapy of normal dosed extended-release tacrolimus and prednisone for 3 months and monotherapy once daily extended-release tacrolimus thereafter up to 3 years after liver transplantation.~Arm 2 once daily combination therapy of low doses sirolimus and extended-release tacrolimus and prednisone for 3 months and combination therapy of low dose sirolimus and extended-release tacrolimus thereafter for up to 3 years after liver transplantation Continue Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician Conversion to sirolimus (3-5 ng/ml) and decrease Advagraf (3-5 ng/ml); 7.5 mg prednisone and lower or discontinue steroids after day 180 at the discretion of the treating physician

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Patient received standard-dose of Tracrolimus Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician
Study: NCT03931967

Intervention type: DIAGNOSTIC_TEST
Intervention: MR-proADM
Description: to evaluate the plasmatic level of MR-proADM and endothelin-1 in the first five days of ICU stay.
Study: NCT01221727

Intervention type: DRUG
Group type: OTHER
Intervention: Denosumab
Description: Eighteen (18) subjects will receive 1 fixed dose administration of denosumab.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: All subjects will receive two oral dose administrations of midazolam.
Study: NCT03525535

Intervention type: OTHER
Intervention: data collection
Description: data from patient included will be collected during the study
Study: NCT01845454

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: trūFreeze™ Spray Cryotherapy
Description: The trūFreeze™ System consists of a console containing a holding tank for medical grade liquid nitrogen and a spray tip CSATM Catheter. The physician uses the console to initiate and control the flow and duration of the cryogen spray. The liquid nitrogen is propelled through a spray CSATM Catheter to the selected site by pressure in the holding tank and freezing techniques are monitored by direct visualization with an endoscope. Once the freezing is completed, the cryogen flow is terminated and the thawing system may be engaged to allow accessory removal. If multiple cycles are used, thawing is initiated at the end of the procedure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: trūFreeze™ Spray Cryotherapy
Description: The trūFreeze™ System consists of a console containing a holding tank for medical grade liquid nitrogen and a spray tip CSATM Catheter. The physician uses the console to initiate and control the flow and duration of the cryogen spray. The liquid nitrogen is propelled through a spray CSATM Catheter to the selected site by pressure in the holding tank and freezing techniques are monitored by direct visualization with an endoscope. Once the freezing is completed, the cryogen flow is terminated and the thawing system may be engaged to allow accessory removal. If multiple cycles are used, thawing is initiated at the end of the procedure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: trūFreeze™ Spray Cryotherapy
Description: The trūFreeze™ System consists of a console containing a holding tank for medical grade liquid nitrogen and a spray tip CSATM Catheter. The physician uses the console to initiate and control the flow and duration of the cryogen spray. The liquid nitrogen is propelled through a spray CSATM Catheter to the selected site by pressure in the holding tank and freezing techniques are monitored by direct visualization with an endoscope. Once the freezing is completed, the cryogen flow is terminated and the thawing system may be engaged to allow accessory removal. If multiple cycles are used, thawing is initiated at the end of the procedure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: trūFreeze™ Spray Cryotherapy
Description: The trūFreeze™ System consists of a console containing a holding tank for medical grade liquid nitrogen and a spray tip CSATM Catheter. The physician uses the console to initiate and control the flow and duration of the cryogen spray. The liquid nitrogen is propelled through a spray CSATM Catheter to the selected site by pressure in the holding tank and freezing techniques are monitored by direct visualization with an endoscope. Once the freezing is completed, the cryogen flow is terminated and the thawing system may be engaged to allow accessory removal. If multiple cycles are used, thawing is initiated at the end of the procedure.
Study: NCT04026061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FMA group
Description: A person-centred, tailored tablet intervention, called FindMyApps (FMA). The intervention consists of the FMA training to use the tablet and the FMA selection tool to help users find apps for self-management and meaningful activities that fit their needs, wishes and abilities

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Receiving an introductory tablet training and some links to websites that recommend usable apps for people with dementia in general
Study: NCT03519464

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Gardasil 9
Description: Gardasil 9 administered as a 0.5ml intramuscular injection in the deltoid region of the upper arm or in the anterolateral area of the thigh, 3-dose regimen of injections given at month 0, month 2, and month 6.
Study: NCT02046577

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo liquid
Study: NCT01472289

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Mononuclear cells (BMMNCs)
Description: Multiple intramuscular injections of concentrated bone marrow derived mononuclear cells (0.5 cc/injection) into the ischemic muscle of the affected limb.
Study: NCT00598910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacor
Description: n-3 PUFA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03029871

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5-yCD/mutTKSR39rep-ADP Adenovirus
Description: oncolytic adenovirus
Study: NCT02830763

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CNT-02
Description: Each subject will take 2.0g of the investigational product orally 3 times a day after every meal. Unless an apparent worsening of symptoms or unacceptable adverse event occurs, the subject will continue to take the investigational product for up to 6 months.
Study: NCT02538003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371 Tablet 800 mg(R)
Description: Reference: taken drug before meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371 Tablet 800 mg(R)
Description: Reference: taken drug before meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371 Tablet 800 mg(T)
Description: Test: taken drug after meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371 Tablet 800 mg(T)
Description: Test: taken drug after meal
Study: NCT00911625

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5 units/kg daily insulin
Description: Participants randomized to receive this intervention will receive a standard-dose of 0.5 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25 units/kg daily insulin
Description: Participants randomized to receive this intervention will receive an experimental dose of 0.25 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.
Study: NCT04280536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort A
Description: Oral FTD/TPI at RP2D will be administered until disease progression, intolerable toxicity or patient withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort B
Description: Oral FTD/TPI at RP2D will be administered until disease progression, intolerable toxicity or patient withdrawal.
Study: NCT02809742

Intervention type: DRUG
Intervention: Ropivacaine
Description: Epidural : automatic intermittent boluses associated with patient controlled bolus using ropivacaine
Study: NCT00771004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone 30 mg, tablets, orally, once daily for one week; increased to Pioglitazone 45 mg, tablets, orally, once daily for up to two weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pioglitazone placebo-matching tablets, orally, once daily for up to three weeks.
Study: NCT02183155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam - low

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam - medium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam - high

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended-release indomethacin
Study: NCT00738413

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferoxamine
Description: Deferoxamine will be administered subcutaneously over 8 hours for 6 days at a dose of 40 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferoxamine
Description: Deferoxamine will be administered subcutaneously over 8 hours for 6 days at a dose of 40 mg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferasirox
Description: Deferasirox will be orally administered at a dose of 30 mg/kg once daily for 6 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: Deferasirox will be orally administered at a dose of 30 mg/kg once daily for 6 days.
Study: NCT02231463

Intervention type: OTHER
Intervention: neutral positioning, PEEP 0 cm H2O
Description: neutral positioning, PEEP 0 cm H2O

Intervention type: OTHER
Intervention: neutral positioning, PEEP 5cm H2O
Description: neutral positioning, PEEP 5cm H2O

Intervention type: OTHER
Intervention: neutral positioning, PEEP 10cm H2O
Description: neutral positioning, PEEP 10cm H2O

Intervention type: OTHER
Intervention: Trendelenburg positioning -20°, PEEP 0 cmH2O
Description: Trendelenburg positioning -20°, PEEP 0 cmH2O

Intervention type: OTHER
Intervention: Trendelenburg positioning -20°, PEEP 5 cmH2O
Description: Trendelenburg positioning -20°, PEEP 5 cmH2O

Intervention type: OTHER
Intervention: Trendelenburg positioning -20°, PEEP 10 cmH2O
Description: Trendelenburg positioning -20°, PEEP 10 cmH2O
Study: NCT04341168

Intervention type: OTHER
Intervention: this study is non- interventional
Description: this study is non- interventional

Intervention type: OTHER
Intervention: this study is non- interventional
Description: this study is non- interventional

Intervention type: OTHER
Intervention: this study is non- interventional
Description: this study is non- interventional
Study: NCT02907710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DDP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDP
Study: NCT00773136

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoprost Suspension
Description: see prior
Study: NCT03612011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Onco-Repair/ Placebo
Description: Cream must be applied twice a day, in the morning and evening, on the hands and feet (palmo-plantar areas and interdigital spaces included) previously cleaned with Atoderm Intensive Foaming Gel, chosen as a standardized hygiene product.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Onco-Repair/ Placebo
Description: Cream must be applied twice a day, in the morning and evening, on the hands and feet (palmo-plantar areas and interdigital spaces included) previously cleaned with Atoderm Intensive Foaming Gel, chosen as a standardized hygiene product.
Study: NCT00941668

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclosan/Copolymer/fluoride toothpaste
Description: Twice daily usage

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium monofluorophosphate toothpaste
Description: Twice daily usage
Study: NCT01866397

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cidofovir pharmacokinetics
Description: Blood samples were drawn before and 15, 30, 60, 120, 240, 360, 720 and 1440 minutes after the start of the cidofovir infusion. Plasma and ultrafiltration samples were collected from the outlet of the ultrafiltrate compartment of the hemofilter.
Study: NCT05104021

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: game
Description: The game is played with a maximum of four people. Beginning points are marked with blue, red, yellow and green colors, the game progress direction is The starting color for the player is determined with the help of arrows. Dice with the biggest number The child who throws starts the game first from the starting point that belongs to him. Play ground Each child who completes a circuit around him reads from his second point. it tries to go inwards (to the world square) in the direction it points. Equivalent to card check box The next child draws one of the face down cards. the instruction written on the back of the card.~implements. Then he puts the card on the back of the other cards. Cards are reward (go forward), penalty (backward) git) cards. Coming second to the same frame during the game The child first starts the game from the starting point of the child in the square. First The child who manages to enter the world square wins the game.
Study: NCT03498898

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chronic use of Beta adrenergic receptor blocker
Description: Chronic use of Beta adrenergic receptor blocker

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chronic use of Beta adrenergic receptor blocker
Description: Chronic use of Beta adrenergic receptor blocker
Study: NCT00408395

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: Seasonal Influenza Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: Seasonal Influenza Vaccine
Study: NCT01127945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: statin
Description: 1. adding atorvastatin 80mg, po on day (1 to 3) acute heart failure therapy~2. acute heart failure therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: statin
Description: 1. adding atorvastatin 80mg, po on day (1 to 3) acute heart failure therapy~2. acute heart failure therapy
Study: NCT00660270

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreatic Surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-interferon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study: NCT02472379

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Writing: Group 1
Description: Writing about experiences with familiar individuals in their lives, once a week for 6 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Writing: Group 2
Description: Writing about experiences with familiar places, once a week for 6 weeks.
Study: NCT02426528

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cultural and Social exposure
Description: The intervention protocol will consist of 24 months of guided exposure and participation in social and cultural activities undertaken in the Casa del Popolo. The participant will be asked to register for a specific type of event (fine arts, performing arts, and social and volunteering activities), duration and date in order that this information can be supplied for further evaluation. Control group participants will be asked to carry on their lives normally and maintain regular cultural and social activity throughout the duration of the study. At twelve months from the beginning of the observation participants of both groups will be checked (intermediate phase).
Study: NCT04295096

Intervention type: DEVICE
Group type: OTHER
Intervention: Peripheral blood mononuclear cell apheresis
Description: Peripheral blood mono-nuclear cell donation for tumor immunotherapy study of Universal CAR-T cells
Study: NCT04166383

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vascular Biogenics (VB)-111
Description: 1E13 or 0.7E13 VP via intravenous (IV) infusion on Day 1 of cycle 1 and continue every 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg of nivolumab via intravenous (IV) infusion on Day 1 of each cycle starting on cycle 2 and continue every 2 weeks
Study: NCT05169216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy
Description: Each week, a sheet of tasks to be executed and a diary were provided to verify compliance with the guidelines:~1. Week 0. Familiarization: Information gathering~2. 1st week. Self-knowledge and concentration: To know sports psychology and mental training. Information on beliefs and expectations in sport.~3. 2nd week: To integrate daily mental training.~4. 3rd week. Trust: To consolidate concentration activation. To integrate and build confidence (in oneself and in the team).~5. 4th week. Application to sports tactics: To apply concentration strategies to your sports practice. To know those strategies that provide the best results for each athlete.~6. 5th and 6th weeks: To integrate the content already provided.~7. 7th week. Link with the team: To strengthen the bond between team members.~8. 8th week. Daily routines: To improve the daily routine prior to the competition.~9. 9th and 10th weeks: To integrate the content already provided.
Study: NCT03692572

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nitrate supplementation
Description: Subjects will drink 70 ml of beet root juice twice a day for 2 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will drink 70 ml of nitrate depleted placebo juice twice a day for 2 weeks.
Study: NCT02966223

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI and HIDA scan
Description: Pre y90 therapy each subject will undergo a HIDA and MRI scan. 3 months post Y90 - Each subject will undergo a second HIDA scan and MRI scan
Study: NCT05767866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YK-029A
Description: Daily dose of YK-029A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YK-029A
Description: Daily dose of YK-029A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YK-029A
Description: Daily dose of YK-029A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YK-029A
Description: Daily dose of YK-029A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YK-029A
Description: Daily dose of YK-029A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YK-029A
Description: Daily dose of YK-029A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YK-029A
Description: Daily dose of YK-029A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YK-029A
Description: Daily dose of YK-029A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YK-029A
Description: Daily dose of YK-029A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YK-029A
Description: Daily dose of YK-029A
Study: NCT04462341

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Water Flosser
Description: Device that uses water under pressure to clean around teeth and under the gums

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual Toothbrush
Description: Plastic handle with nylon bristles to clean teeth

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Toothbrush
Description: Plastic handle with nylon bristles to clean teeth
Study: NCT00075088

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrocardiogram (ECG) Intervention
Description: Pre-hospital electrocardiographic (ECG) monitoring with special software to detect myocardial ischemia and to automatically transmit an ECG to the destination hospital emergency department with a voice alarm announcing Incoming ECG from the field and print out in the ED.

Intervention type: OTHER
Group type: OTHER
Intervention: Routine Clinical Practice
Description: ECG in the ED as part of routine clinical practice.
Study: NCT02017639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sarilumab SAR153191 (REGN88)
Description: Pharmaceutical form:Prefilled syringe of sarilumab solution Route of administration: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: Pharmaceutical form:Film-coated 20 mg Tablet Route of administration: oral
Study: NCT00504153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01909427

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injections (SC) every 4 weeks through Week 12

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CNTO 6785 200 mg
Description: CNTO 6785 200 mg SC every 4 weeks from Week 16 through Week 28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 6785 200 mg
Description: CNTO 6785 200 mg SC every 4 weeks through Week 28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 6785 100 mg
Description: CNTO 6785 100 mg SC every 4 weeks through Week 28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 6785 50 mg
Description: CNTO 6785 50 mg SC every 4 weeks through Week 28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 6785 15 mg
Description: CNTO 6785 15 mg SC every 4 weeks through Week 28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: MTX at the same stable dose through Week 32, that participants were receiving prior to screening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: MTX at the same stable dose through Week 32, that participants were receiving prior to screening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: MTX at the same stable dose through Week 32, that participants were receiving prior to screening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: MTX at the same stable dose through Week 32, that participants were receiving prior to screening.
Study: NCT04276896

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs
Description: Patients will receive approximately 5x10\^6 LV-DC vaccine and 1x10\^8 CTLs via sub-cutaneous injections and iv infusions, respectively.